Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight
The protein expression market is primarily driven by the increasing prevalence of chronic diseases, which in turn fuels greater demand for biopharmaceuticals, including monoclonal antibodies and vaccines. Furthermore, the market is being significantly boosted by ongoing advancements in research areas like proteomics, structural biology, therapeutic protein development, and personalized medicine, along with continuous technological innovations in protein expression. These factors are expected to drive market growth throughout the forecast period from 2025 to 2032.
New York, USA, June 19, 2025 (GLOBE NEWSWIRE) -- Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight
The protein expression market is primarily driven by the increasing prevalence of chronic diseases, which in turn fuels greater demand for biopharmaceuticals, including monoclonal antibodies and vaccines. Furthermore, the market is being significantly boosted by ongoing advancements in research areas like proteomics, structural biology, therapeutic protein development, and personalized medicine, along with continuous technological innovations in protein expression. These factors are expected to drive market growth throughout the forecast period from 2025 to 2032.
DelveInsight’s Protein Expression Market Insights report provides the current and forecast market analysis, individual leading protein expression companies’ market shares, challenges, protein expression market drivers, barriers, trends, and key market protein expression companies in the market.
Key Takeaways from the Protein Expression Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global protein expression market during the forecast period.
- In the host cell expression segment of the protein expression market, the cell-free protein expression category held a significant revenue share in 2024.
- Notable protein expression companies such as Agilent Technologies Inc., Thermo Fisher Scientific Inc., Merck KGaA, Lonza Bioscience, Promega, BioLinker, Biotechrabbit, CellFreeSciences, Creative Biolabs, QIAGEN, Biocon Biologics Ltd., Takara Bio, Inc., Bio-Rad Laboratories Inc., Genscript Biotech Corporation, Hudson Robotics Inc., BD, Oxford Expression Technologies, and several others are currently operating in the protein expression market.
- In June 2024, Syngene International Ltd., a global contract research, development, and manufacturing organization (CRDMO), unveiled a new protein production platform. This platform integrates a cell line and transposon-based technology licensed from Swiss biotech company ExcellGene with Syngene’s proprietary clone selection and development processes.
To read more about the latest highlights related to the protein expression market, get a snapshot of the key highlights entailed in the Global Protein Expression Market Report
Protein Expression Overview
Protein expression refers to the process by which proteins are synthesized, modified, and regulated in living organisms. It begins with the transcription of a gene’s DNA sequence into messenger RNA (mRNA), which is then translated by ribosomes into a specific protein. This process is fundamental to cellular function, as proteins are responsible for nearly all biological activities, including enzymatic reactions, structural support, signal transduction, and immune responses. Protein expression can be naturally occurring within an organism or artificially induced in laboratory settings using expression systems like bacterial, yeast, insect, or mammalian cells.
In biotechnology and pharmaceutical research, protein expression is critical for producing recombinant proteins used in therapies, vaccines, and diagnostics. Scientists often manipulate gene sequences and optimize expression conditions to maximize yield and functionality of the target protein. Factors such as the choice of host organism, promoter strength, codon optimization, and post-translational modifications influence expression efficiency. Advances in synthetic biology and gene editing have significantly improved the ability to express complex proteins, paving the way for innovative treatments and industrial applications.
Protein Expression Market Insights
North America held the largest share of the global protein expression market in 2024. This dominance is primarily attributed to the region's increasing cancer prevalence, which is driving demand for protein expression technologies essential for cancer research, diagnostics, and treatment. Additionally, collaborative efforts between academic institutions and companies to advance innovative protein expression solutions, along with rapid technological progress and the rising need for advanced protein-based therapeutics, are significantly contributing to market growth in the region.
Strategic collaborations aimed at developing next-generation protein expression platforms continue to support market expansion. Many industry players are adopting such strategies to strengthen their presence. For example, in August 2022, BioIVT acquired Cypex, broadening its protein portfolio and enhancing its drug discovery and development offerings.
Furthermore, the rising demand for biopharmaceuticals such as monoclonal antibodies and vaccines is another key driver. According to the U.S. Food and Drug Administration (2024), by the end of 2023, more than 100 monoclonal antibodies had been approved for a range of conditions including cancer, autoimmune disorders, infectious diseases, and inflammation. A recent example includes the FDA’s accelerated approval in May 2024 of tarlatamab-dlle (MDELLTRA), a bispecific T cell engager targeting DLL3 and CD3, designed with Fc mutations to prolong its half-life and improve therapeutic efficacy through enhanced T cell-driven tumor cell destruction. The development and approval of such complex biologics underscore the need for efficient and scalable protein expression systems capable of producing high-quality therapeutics.
In summary, these factors collectively are expected to drive significant growth in the North American protein expression market throughout the forecast period.
To know more about why North America is leading the market growth in the protein expression market, get a snapshot of the Protein Expression Market Outlook
Protein Expression Market Dynamics
The protein expression market is witnessing significant growth, driven primarily by the expanding demand for biopharmaceuticals, including monoclonal antibodies, therapeutic proteins, and vaccines. As the global burden of chronic and infectious diseases rises, pharmaceutical and biotech companies are increasingly investing in advanced protein expression systems to accelerate the discovery and production of novel therapeutics. Additionally, the success of mRNA-based vaccines and other protein-based biologics has bolstered confidence in this domain, prompting both public and private stakeholders to allocate substantial resources for research and development.
Technological advancements in expression systems, such as bacterial, yeast, insect, and mammalian cell-based platforms, have greatly enhanced the efficiency, yield, and scalability of protein production. Innovations like cell-free expression systems and synthetic biology are also emerging as game-changers, offering faster and more flexible alternatives to traditional cell-based approaches. These platforms are increasingly being optimized for high-throughput screening, structural biology, and industrial enzyme production, expanding the market’s reach beyond healthcare into sectors like agriculture, food, and environmental science.
Another major factor shaping the market dynamics is the surge in personalized medicine and precision therapeutics. Protein-based biomarkers and therapeutic proteins play a crucial role in tailoring treatments to individual patient profiles. Consequently, there is growing demand for specialized protein expression tools that can support the development of personalized drugs. Additionally, academic and contract research organizations (CROs) are driving collaborative projects with pharmaceutical companies to explore new targets and validate protein interactions, further stimulating market expansion.
However, the market also faces several challenges, including the high cost of protein expression systems and the complexity involved in achieving proper folding and post-translational modifications, particularly in eukaryotic expression systems. Regulatory hurdles and quality control issues can also delay time-to-market for new therapeutics. Furthermore, intellectual property concerns and the competitive landscape marked by numerous small- and mid-sized players pose risks to market consolidation and growth strategies.
Despite these challenges, the protein expression market is expected to grow robustly between 2025 and 2032, supported by favorable government funding, increasing demand for biologics, and the growing use of recombinant proteins in various industrial applications. Emerging markets, particularly in Asia-Pacific and Latin America, are becoming attractive due to lower manufacturing costs and expanding biotech infrastructure, suggesting that the market will continue to evolve dynamically across geographies and sectors.
Get a sneak peek at the protein expression market dynamics @ Protein Expression Market Trends
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2022–2032 |
| Protein Expression Market CAGR | ~8% |
| Protein Expression Market Size by 2032 | USD 6.4 Billion |
| Key Protein Expression Companies | Agilent Technologies Inc., Thermo Fisher Scientific Inc., Merck KGaA, Lonza Bioscience, Promega, BioLinker, Biotechrabbit, CellFreeSciences, Creative Biolabs, QIAGEN, Biocon Biologics Ltd., Takara Bio, Inc., Bio-Rad Laboratories Inc., Genscript Biotech Corporation, Hudson Robotics Inc., BD, Oxford Expression Technologies, among others |
Protein Expression Market Assessment
-
Protein Expression Market Segmentation
- Protein Expression Market Segmentation By Cell Expression: Prokaryotic Expression, Eukaryotic Expression, Yeast Expression, Insect Based Expression, Mammalian Based Expression, and Cell Free Expression
- Protein Expression Market Segmentation By Product: Reagents & Kits, Vectors, Competent Cells, and Others
- Protein Expression Market Segmentation By Application: Therapeutics, Industrial, and Research
- Protein Expression Market Segmentation By End User: Pharmaceuticals & Biotechnology Companies, Research Centers, and Others
- Protein Expression Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the protein expression market are set to emerge as the trendsetter explore @ Protein Expression Companies
Table of Contents
| 1 | Protein Expression Market Report Introduction |
| 2 | Protein Expression Market Executive Summary |
| 3 | Competitive Landscape |
| 4 | Regulatory Analysis |
| 5 | Protein Expression Market Key Factors Analysis |
| 6 | Protein Expression Market Porter’s Five Forces Analysis |
| 7 | Protein Expression Market Layout |
| 8 | Protein Expression Market Company and Product Profiles |
| 9 | KOL Views |
| 10 | Project Approach |
| 11 | About DelveInsight |
| 12 | Disclaimer & Contact Us |
Interested in knowing the protein expression market by 2032? Click to get a snapshot of the Protein Expression Market Analysis
Related Reports
Vaccines Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccines companies, including GlaxoSmithKline, Bharat Biotech, AstraZeneca, Bavarian Nordic A/S, BioNTech, Sanofi, Merck & Co., Inc, Pfizer Inc, Moderna, Meiji Holdings Co., Ltd., EMERGENT, CSL Limited, Johnson & Johnson, VBI Vaccines Inc., Valneva SE., Novavax, CanSinoBIO, Biokangtai, Dynavax Technologies, Zhi Fei Biological, among others.
Biopharmaceuticals Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biopharmaceuticals companies, including AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Novo Nordisk AS, Pfizer Inc., GSK plc., F. Hoffmann-La Roche Ltd, Merck KGaA, Sanofi SA, AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Company Limited, UCB S.A., Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Biogen, Serum Institute of India, among others.
Monoclonal Antibody Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key monoclonal antibody companies, including Novartis, Gmax Biopharm, Omeros Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook Therapeutics, Omeros Corporation, Novo Nordisk, Merck KGaA, Bristol-Myers Squibb, Jacobio Pharmaceuticals, among others.
Vaccine Contract Manufacturing Market
Vaccine Contract Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccine contract manufacturing companies, including Sanofi, Biovac, Emergent BioSolutions Inc., Lonza Group, Catalent Inc., Boehringer Ingelheim BioXcellence, Wockhardt, WuXi Biologics, Moderna, Inc., Syngene International, Meridian Life Sciences, Eurogentec, IDT Biologika, Serum Institute of India, GlaxoSmithKline (GSK), Soligenix Inc., Curia, Cobra Biologics, BioReliance, Recipharm, Jubilant HollisterStier, among others.
Biopharmaceuticals Contract Manufacturing Market
Biopharmaceuticals Contract Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
